Search for a trial

A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second line Everolimus until progression in patients with advanced or metastatic clear cell renal cancer.

Primary objectivesThe primary objective is to assess the progression-free survival (PFS) of patients who receive bi-monthly rotations of Pazopanib and Everolimus versus patients who receive Pazopanib as a first line treatment. Secondary…

A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney

• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…

Evaluating the Effect of Pre-TURBT Intravesical Instillation
of Mitomycin C (MMC) Mixed With TC-3 Gel
in Patients with Non Muscle Invasive Bladder Cancer (NMIBC)

Evaluation of the effect of pre-TURBT intravesical instillations of MMC mixed with TC-3 Hydrogel on bladder lesion(s) of NMIBC patients.a. Comparison of the effect of pre-TURBT instillations with MMC mixed with TC-3 Hydrogel on bladder lesion(s) to…

A randomized phase IIa study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients

To show immunologic efficacy of tumor-peptide loaded natural DC in mCRPC patients. Further we will demonstrate that natural DC vaccinations are safe, feasible and clinically effective. Also the therapy effect on quality of life will be studied.

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus standard of care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma

Primary Objectives• To compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to standard of care in patients with previously untreated and advanced non-clear cell RCC, Secondary Objectives• To compare the OS rate at 6 and 18…

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy

This study has been transitioned to CTIS with ID 2023-506146-23-00 check the CTIS register for the current data. Cohorts 1, 2, and 3 only:The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with…

Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)

This study has been transitioned to CTIS with ID 2024-515514-40-00 check the CTIS register for the current data. The primary objective is to investigate the rate of pathological responses following different neoadjuvant immunotherapy combinations in…

The pharmacological effects of using cabozantinib with a light breakfast

The primary is to investigate to the change in exposure to cabozantinib by taking cabozantinib with a light breakfast compared to taking cabozantinib in fasted state. The secondary objectives are to investigate the analytical feasibility of…

A Randomized, Open-label (formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Primary ObjectiveTo assess whether a starting dose of lenvatinib 14 mg in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile…